Results 111 to 120 of about 868 (155)
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. [PDF]
World J RadiolHao K, Paik AJ, Han LH, Makary MS.
europepmc +1 more source
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab. [PDF]
Liver CancerJeschke M +8 more
europepmc +1 more source
European Journal of Surgical Oncology, 2021 The aim of the study is to estimate the cost-effectiveness of TheraSphere against other embolic treatments in a population with early to intermediate stage hepatocellular carcinoma (HCC) who are unresectable at presentation and are eligible for transarterial embolization (TAE), conventional transarterial chemoembolization (cTACE) or drug-eluting bead ...
Stuart Mealing +2 more
exaly +4 more sources
European Journal of Nuclear Medicine and Molecular Imaging, 2009 We report a first experience involving the use of (90)Y radiolabelled microspheres (TheraSphere) for the treatment of mainly primary hepatic tumours.Treatment using TheraSphere microspheres was planned in 15 patients (13 with hepatocellular carcinoma, 2 with neuroendocrine tumour metastases).
Jean-Luc Raoul +2 more
exaly +4 more sources
HCC Radioembolization with Yttrium-90 Glass Microspheres (TheraSphere)
, 2018 Intraarterial radioembolization (RE) using microspheres labelled with the high-energy beta-emitter yttrium-90 (90Y) is an innovative local therapy for hepatocellular carcinoma (HCC). This procedure allows the tumour to be irradiated with a dose higher than that allowed by whole-liver external beam radiation treatment. The TheraSphere (TheraSphere_BTG®)
Carlo Spreafico +2 more
exaly +3 more sources
CardioVascular and Interventional Radiology, 2006 In Canada and Europe, yttrium-90 microspheres (TheraSphere); MDS Nordion, Ottawa, Canada) are a primary treatment option for primary and secondary hepatic malignancies. We present data from 30 patients with hepatocellular carcinoma (HCC) and metastatic liver disease treated with TheraSphere from a single academic institution to evaluate the ...
Riad Salem +2 more
exaly +4 more sources
Outcomes of therasphere radioembolization for neuroendocrine metastases.
Journal of Clinical Oncology, 2015 371 Background: Neuroendocrine tumors (NET) are a rare group of tumors with variable biologic activity that have a propensity for hepatic metastases. Complete surgical resection or debulking is the standard of care while chemotherapy is reserved for unresectable disease. However, liver directed therapy utilizing radioembolization with yttrium-90 (y90)
Andrea M. Abbott +10 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Use of Yttriurn-90 TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
American Surgeon, 2004This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment ...
Fong Y Tsai, Kenneth M Tokita
exaly +3 more sources